Bain Capital

About Us
About us Explore

Overview

Purpose and values

How we partner

Our global presence
Committed to lasting impact
Our purpose, in our words
Businesses
Private Equity
HOW WE CREATE VALUE
Transforming businesses through deep sector expertise and capabilities.
HOW WE INVEST
Global Private Equity>
Double Impact>
Insurance>
Growth & Venture
HOW WE CREATE VALUE
Accelerating seed-to-scale growth in partnership with visionary leaders.
HOW WE INVEST
Ventures>
Life Sciences>
Tech Opportunities>
Crypto>
Capital Solutions
HOW WE CREATE VALUE
Structuring bespoke solutions across asset types, industries, markets, and business life cycles.
HOW WE INVEST
Special Situations>
Partnership Strategies>
Credit & Capital Markets
HOW WE CREATE VALUE
Enabling growth through innovative fund strategies and investment solutions across the capital structure.
HOW WE INVEST
Credit>
Public Equity>
Real Assets
HOW WE CREATE VALUE
Building the next generation of real assets.
HOW WE INVEST
Real Estate>
Special Situations>
Sustainability & Impact
Sustainability & Impact Explore

Active governance & stewardship

Sustainable growth & reducing climate impact

Fair employment, engagement & well-being

Diversity, equity & inclusion

Community engagement
2025 REPORT June 26, 2025
Driving sustainable value
People
Careers
CAREERS Explore

Opportunity

Growth

Join us
Fulfill your potential
Our people are the heart of our advantage
News
NEWS View All

Press releases

In the news
PRESS RELEASES Special Situations Jul 01, 2025

Warner Music Group and Bain Capital Announce Launch of Joint Venture to Invest Up To $1.2 Billion in Iconic Music Catalogs

EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases

EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases

Share this page

Bain Capital

Local Sites

OUR BUSINESSES

Private Equity

HOW WE CREATE VALUE

HOW WE INVEST

Growth & Venture

HOW WE CREATE VALUE

HOW WE INVEST

Capital Solutions

HOW WE CREATE VALUE

HOW WE INVEST

Credit & Capital Markets

HOW WE CREATE VALUE

HOW WE INVEST

Real Assets

HOW WE CREATE VALUE

HOW WE INVEST

EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases

Share this page